Syros Pharmaceuticals (SYRS) Tops Q1 EPS by 23c, Revenues Beat

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/5/2026

1. NVDA
2. PTC
3. PCVX
4. SPY
5. META
6. MSFT
7. AMD
8. GMAB
9. USO
10. AMZN

Go back to Syros Pharmaceuticals (SYRS) Tops Q1 EPS by 23c, Revenues Beat

Syros Reports First Quarter 2021 Financial Results and Highlights Key Accomplishments and Upcoming Milestones

May 6, 2021 7:31 AM EDT

Enrolling Patients in Phase 3 Trial of SY-1425 in Combination with Azacitidine in RARA-Positive Newly Diagnosed Higher-Risk MDS Patients

Today Announced Three-Part KOL Webinar Series on Its Portfolio of Investigational Targeted Hematology Therapies, Beginning May 2021

On Track to Achieve 2021 Milestones, Including Initiation of SY-1425 and SY-2101 Clinical Trials in 2H 2021 and Additional Dose-Escalation Data for SY-5609 in 3Q 2021

Management to Host Conference Call at 8:30 a.m. ET Today

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ:... More